Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $77.00 target price on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group increased their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $18.61 on Thursday. Capricor Therapeutics has a 1-year low of $2.87 and a 1-year high of $23.40. The company has a market capitalization of $845.01 million, a P/E ratio of -17.56 and a beta of 4.00. The firm’s 50 day simple moving average is $15.21 and its 200 day simple moving average is $8.50.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics in the 3rd quarter worth approximately $3,806,000. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares in the last quarter. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics in the third quarter worth $2,324,000. State Street Corp boosted its holdings in Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics during the 2nd quarter valued at $426,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.